The Growing Link Between HIV and Cardiovascular Disease

For decades, HIV infection was primarily understood as an immunological disease. However, as advancements in antiretroviral therapy (ART) have dramatically increased life expectancy for people living with HIV, a significant and growing concern has emerged: the increased risk of cardiovascular disease (CVD). This article explores the complex relationship between HIV and CVD, examining the evolving understanding of its pathogenesis, current diagnostic approaches, and future research directions.

The Evolving Landscape of HIV and Heart Health

Early in the AIDS epidemic, cardiac abnormalities were observed, often linked to profound immunodeficiency. Studies indicated that cardiac involvement in AIDS patients ranged from 28% to 73%. Before the widespread apply of ART, HIV-associated cardiomyopathy, a weakening of the heart muscle, was a primary manifestation of cardiac disease in this population.

With the advent of ART, which effectively suppresses viral load and restores immune function, the nature of HIV-associated CVD has shifted. Even as the incidence of severe cardiomyopathy has decreased, people living with HIV continue to experience a higher incidence of various cardiovascular pathologies. Research demonstrates that even with successful viral suppression, the risk of CVD remains elevated.

Understanding the Pathogenesis of HIV-Associated CVD

The mechanisms driving CVD in people living with HIV are multifaceted and not fully understood. Several factors are believed to contribute, including:

• Direct Viral Effects: While ART reduces viral load, HIV can still directly impact the cardiovascular system, potentially causing inflammation and endothelial dysfunction.
• Chronic Inflammation: HIV infection is characterized by chronic immune activation and inflammation, even in individuals on ART. This chronic inflammation contributes to atherosclerosis, the buildup of plaque in the arteries.
• ART-Related Factors: Some older ART regimens were associated with metabolic abnormalities, such as dyslipidemia (abnormal cholesterol levels) and insulin resistance, which increase CVD risk. However, newer ART formulations generally have more favorable metabolic profiles.
• Traditional CVD Risk Factors: People living with HIV often have a higher prevalence of traditional CVD risk factors, such as hypertension, smoking, and diabetes.

Recent reviews emphasize the need to further investigate the molecular mechanisms underlying HIV-associated cardiomyopathy.

Diagnosing Cardiovascular Disease in People Living with HIV

Diagnosing CVD in people living with HIV requires a comprehensive approach, including:

• Clinical Evaluation: Assessing symptoms such as chest pain, shortness of breath, and edema (swelling).
• Electrocardiogram (ECG): To evaluate heart rhythm and electrical activity.
• Echocardiogram: An ultrasound of the heart to assess its structure, and function.
• Cardiac Magnetic Resonance Imaging (MRI): Provides detailed images of the heart and can detect subtle abnormalities.
• Biomarkers: Measuring levels of cardiac biomarkers, such as troponin, to detect heart damage.

Advances in cardiac imaging modalities are crucial for early detection and accurate diagnosis of CVD in this population.

Future Directions and Research

Further research is needed to fully elucidate the complex interactions between HIV and CVD. Key areas of focus include:

• Investigating the long-term effects of ART on cardiovascular health.
• Identifying novel biomarkers for early detection of CVD risk.
• Developing targeted interventions to reduce inflammation and improve cardiovascular function in people living with HIV.
• Understanding the specific challenges faced by populations originating from high-endemic regions, such as sub-Saharan Africa.

Addressing these research gaps will be essential for improving the cardiovascular health and overall well-being of people living with HIV.